Noom launches GLP-1 Rx program with compounded semaglutide at competitive prices.
Noom has launched a GLP-1 Rx program offering compounded semaglutide, an off-brand alternative to Novo Nordisk's Ozempic and Wegovy, at competitive prices—$149 for the first month and $279 afterward. The program emphasizes behavior modification for sustainable weight loss and includes a taper-off option. However, compounded versions may pose safety risks due to manual dosing, leading to potential overdoses. The market for affordable weight loss medications is becoming increasingly competitive.
September 12, 2024
10 Articles